statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Buy Rating Affirmed for Unicycive Therapeutics Amid Positive Clinical Feedback and Strong Market Entry Potential

Maxim Group analyst Jason McCarthy has reiterated their bullish stance on UNCY stock, giving a Buy rating today. Jason McCarthy has given his Buy r...

Buy Rating for Unicycive Therapeutics Backed by Strong OLC Patient Preference and Positive Revenue Projections

Ed Arce, an analyst from H.C. Wainwright, maintained the Buy rating on Unicycive Therapeutics (UNCY Research Report). The associated price target...

Unicycive Therapeutics initiated with bullish view at Piper Sandler, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

HC Wainwright Reaffirms Buy Rating for Unicycive Therapeutics (NASDAQ:UNCY)

HC Wainwright reiterated their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY - Free Report) in a report published on Monday, Benzinga reports. The firm currently has a $4.50 price...

Buy Rating Affirmed for Unicycive Therapeutics Amidst Positive Milestones and Solid Financial Footing

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics (UNCY Research Report), with a price t...

Short Interest in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Rises By 62.0%

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 56,700 shares, a...

UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
UNCY stock results show that Unicycive Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
The post...

Unicycive Therapeutics reports FY23 EPS ($1.28), consensus ($1.24)

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

Oxylanthanum Carbonate (OLC) Topline Data Expected in Q2 2024 UNI-494 Granted Orphan Drug Designation in Delayed Graft Function of Acute Kidney Injury UNI-494 Phase 1 Single Ascending Dose...

Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress

LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Volume	1.9M
52-Wk High	$1.82
52-Wk Low	$0.339

UNCY Unicycive Therapeutics Inc

About

Feed

News

Fundamentals